Based on the present evidences, we propose that any causative-agent targeting immunotherapy for brain disorders, whether it uses active or passive strategies, or whether the causative agent is Aβ, tau, α-synuclein, or other factors, can result in neuronal damage, as long as the antibody with effector function and causative agents located on neuronal surface. Here, MAPT is linked to brain disorder.